Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Advance Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$938,721

87 payments

Through program year 2025, Advance Clinical Research is reported as receiving $938,721 in research payments, across 87 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $39,357 14
2024 Research $170,169 28
2023 Research $210,896 21
2022 Research $39,798 5
2021 Research $21,141 4
2020 Research $51,275 4
2019 Research $406,085 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $221,025 19 payments
  2. Pfizer Inc. $212,325 4 payments
  3. Genentech, Inc. $191,014 35 payments
  4. Celgene Corporation $101,827 8 payments
  5. AstraZeneca UK Limited $97,882 5 payments
  6. Chiesi USA, Inc. $86,898 13 payments
  7. Teva Pharmaceuticals USA, Inc. $17,750 1 payment
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $10,000 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $211,291 2 payments
  2. Roche Cancer Screening Collection Study $191,014 35 payments
  3. A Phase IV, 12-Week, Randomised, Double-Blind, Triple Dummy Study to C $107,764 5 payments
  4. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $99,527 13 payments
  5. Observational Study of Obstructive Lung Disease NOVELTY $97,882 5 payments
  6. PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) $53,337 3 payments
  7. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $45,574 4 payments
  8. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $41,324 9 payments
  9. PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202) $27,201 2 payments
  10. A Randomized, Multiple-Dose, Blinded, Placebo-Controlled, Parallel-Design, Multiple-Center, Clinical Study to Evaluate the Therapeutic Equivalence of Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg to ADVAIR DISKUS 100/50 (Fluticasone Propionate/Salmeterol) Inhalation Powder, in Subjects With Asthma $17,750 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record